Results: ECGs of LPF-VT (n=183) were compared with 61 ECGs showing RBBB and LAHB. Univariate analysis demonstrated differences in QRS axis, limb (I, aVR) and precordial (V1, V2, V6) ECG leads. On multivariate logistic regression analysis, LPF-VT was more often associated with atypical RBBB-like V1 morphology (OR=5.1, 95% CI=1.7-15.6, p=0.004), positive QRS in aVR (OR=19.2, 95% CI=4.3-86.5, p<0.001), V6 R/S ratio ≤1 (OR=6.7, 95% CI=1.6-28.5, p=0.01) and QRS ≤140ms (OR=7.7, 95% CI=2.9-20.3, p<0.001). Using these 4 variables a prediction model was developed. Patients with 3 out 4 positive variables had high probability of having LPF-VT, whereas patients with <1 positive variable always had RBBB plus LAHB.
Conclusions:The morphological ECG characteristics of LPF-VT were defined and a high accurate tool for correctly differentiating LPF-VT from RBBB and LAHB aberrancy was developed. Background: For restoration of sinus rhythm, electrical cardioversion (ECV) is the most effective therapy. The delay in performing ECV could lead to increased left atrial electric remodeling and increased atrial fibrillation (AF) recurrences. The aim of our study was to compare two ECV strategies with different delay times and value their influence in AF recurrence. Methods: A total of 401 consecutive patients with paroxismal AF (duration less than 7 days), that went under ECV between October 2012 and March 2016, were included. They were divided into two different therapeutical strategy groups: a) transesophageal echocardiography and early ECV before 10 days since AF diagnosis was made (n=178) and b) 3 week oral anticoagulation treatment and late ECV. (n=221). ECV effectiveness and AF recurrences were analysed in weeks 4 and 8 after ECV was performed. Results: Demographic characteristics were similar in both groups. Mean time from AF diagnosis to ECV was shorter in early ECV group. (3,01 vs. 26,82 days; p<0,001). There were no significant differences in the use of betabloquers (18,8% vs 22,9%; p=0,154), nor in the left atrial dilatation degree (47,1% vs 52,9%; p=0,277) between both groups. A greater number of patients under antiarrythmic drugs was found in the late ECV strategy group. (32,7% vs 21,9%; p 0,02). No difference in inmediate ECV effectiveness was observed between the two groups. (early: 89,5% vs.late: 88,2%; p=NS), A higher AF recurrence rate was documented in late ECV group; 4 weeks after ECV (38% vs. 26,2%; p=0,017), and 8 weeks after ECV (41,6% vs 26,3%, p=0,002).
P6377 | BEDSIDE